VEGFA and hepatocellular carcinoma: Subsequent to the study presented herein, the combination of atezolizumab, an anti‐PD‐L1 antibody, and bevacizumab, a monoclonal antibody to VEGF, were found to offer superior overall survival to sorafenib in a randomized phase 3 study in treatment‐naive advanced HCC.9